U.S. markets closed
  • S&P 500

    +39.95 (+1.06%)
  • Dow 30

    +321.83 (+1.05%)
  • Nasdaq

    +99.11 (+0.90%)
  • Russell 2000

    +19.77 (+1.16%)
  • Crude Oil

    +2.70 (+2.55%)
  • Gold

    +5.60 (+0.31%)
  • Silver

    -0.51 (-2.50%)

    -0.0057 (-0.54%)
  • 10-Yr Bond

    -0.0830 (-2.79%)

    -0.0072 (-0.59%)

    -0.5530 (-0.41%)

    +32.44 (+0.17%)
  • CMC Crypto 200

    +0.70 (+0.17%)
  • FTSE 100

    -0.63 (-0.01%)
  • Nikkei 225

    -457.42 (-1.73%)

The Zacks Analyst Blog Highlights: Eli Lilly and Company, Union Pacific Corporation, and Freeport-McMoRan Inc

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

For Immediate Release

Chicago, IL – February 14, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Company LLY, Union Pacific Corporation UNP, and Freeport-McMoRan Inc. FCX.

Here are highlights from Friday’s Analyst Blog:

Top Stock Reports for Eli Lilly, Union Pacific and Freeport McMoRan

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Union Pacific Corporation (UNP), and Freeport-McMoRan Inc. (FCX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Eli Lilly have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+16.8% vs. +18.9%), with favorable demand trends for drugs like Trulicity and Taltz expected to help drive Lilly’s outperformance.

Eli Lilly recently submitted regulatory applications for tirzepatide for type II diabetes and donanemab for early Alzheimer's disease, both of which have multibillion dollar sales potential. It is regularly adding promising new pipeline assets through business development deals. Generic competition for several drugs and rising pricing pressure, however, remain as the major top-line headwinds.

(You can read the full research report on Eli Lilly here >>>)

Union Pacific shares have gained +7.4% in the past six months against the Zacks Rail industry’s rise of +5.7%. The Zacks analyst is impressed with Union Pacific's efforts to reward its shareholders even in the current uncertain times.

In December 2021, UNP's board announced a 10% hike in its quarterly dividend to $1.18 per share. Union Pacific's strong free cash flow generating ability has been supporting its shareholder-friendly activities. An escalation in fuel costs due to rising oil prices, however, have led to a 7% rise in operating expenses. Union Pacific cut its 2021 volume growth outlook due to supply-chain woes.

(You can read the full research report on Union Pacific here >>>)

Shares of Freeport-McMoRan have gained +6.9% in the last three months against the Zacks Mining - Non Ferrous industry’s loss of –8.3%. The Zacks analyst believes that Freeport’s initiatives to reduce debt will boost its financial position.

Freeport is also conducting exploration activities near its existing mines with a focus to expand reserves that will support additional future production capacity. FCX is well-positioned to benefit from automotive electrification, which is positive for copper as electrical vehicles are copper intensive. Higher copper prices are also expected to support margins. FCX’s margins are likely to be further supported by lower interest rates.

(You can read the full research report on Freeport-McMoRan here >>>)

Other noteworthy reports we are featuring today include Boston Scientific Corp. (BSX) and Marriott International, Inc. (MAR).

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?

From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.

See Stocks Now >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339



Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
FreeportMcMoRan Inc. (FCX) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Union Pacific Corporation (UNP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research